Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Res. 2011 May 24;71(11):3972–3979. doi: 10.1158/0008-5472.CAN-10-3852

Figure 2.

Figure 2

6BIO inhibits phosphorylation of JAK family kinases in cells and JAK enzymatic activity in vitro. A, A2058 human melanoma cells were treated with 6BIO at various concentrations for 4 h. Cells were lysed for Western blot analysis using antibodies specific to p-Jak1, Jak1, p-Jak2, Jak2, p-Tyk2, Tyk2, and β-Actin . B, A2058 human melanoma cells were treated with 6BIO at various concentrations for 24 h. Cells were lysed for Western blot analysis using antibodies specific to p-Jak1, Jak1, p-Jak2, Jak2, p-Tyk2, Tyk2, and β-Actin. C, A2058 human melanoma cells were treated with 10 μmol/L of 6BIO for various lengths of time. Cells were lysed for Western blot analysis using antibodies specific to p-Jak1, Jak1, p-Jak2, Jak2, p-Tyk2, Tyk2, and β-Actin. D, in vitro kinase assays of JAK1, JAK2 and TYK2 were conducted using recombinant JAK proteins, substrates and 33P-labeled ATP in the presence of 6BIO at various concentrations. Radioactivity was measured for determination of kinase activity.